Shraddha Patel, PA
Medical · Newark, DENPI 1790088128
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 65.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $1,090 and has fallen 62.4% since, to $410 in 2025.
Across 43 payments — averaging $79.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- EMD Serono, Inc.$296
- Biogen$205
- Genentech, Inc.$163
- Sanofi$136
- Johnson & Johnson$99
- plus $260 from 9 others
What the payments were for
- Consulting fees$1504%
- Travel & lodging$1,85955%
- Food & beverage$1,29538%
- Education$993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 20 | $2,243 |
| EMD Serono, Inc. | 4 | $296 |
| Biogen | 2 | $205 |
| Genentech, Inc. | 1 | $163 |
| Sanofi | 4 | $136 |
| Johnson & Johnson | 1 | $99 |
| UCB, Inc. | 3 | $66 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Neurelis, Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $33 |
| Genentech USA, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,581
- Inspire Upper Airway Stimulation System$449
- OCREVUS$163
- TYSABRI$150
How this compares
$3,403 in reported general payments places this provider in the 85th percentile of 73 medical providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 11 | $431,322 |
| Kesimpta PenOfatumumab | 22 | $188,073 |
| VumerityDiroximel Fumarate | 20 | $175,253 |
| FingolimodFingolimod Hcl | 51 | $166,934 |
| AmpyraDalfampridine | 18 | $90,693 |
| Glatiramer Acetate | 21 | $47,877 |
| Dalfampridine ErDalfampridine | 76 | $32,451 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $21,450 |
| UbrelvyUbrogepant | 13 | $12,991 |
| MyrbetriqMirabegron | 20 | $12,278 |
| Gabapentin | 191 | $5,452 |
| Levetiracetam | 88 | $5,203 |
| Carbamazepine ErCarbamazepine | 29 | $3,562 |
| Lisdexamfetamine Dimesylate | 12 | $2,909 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $2,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $163 | $431,32211 claims |
| BiogenVumerity | $205 | $175,25320 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $12,27820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 73 medical providers in Delaware.
Other medical in Newark
- Gwen DalphonNewark$116K
- Stephanie CarlinoNewark$9K
- Michele ComptonNewark$4K
- Robert KondosNewark$3K
- Lori KleimanNewark$2K
- Sherri CampbellNewark$977
- Amanda MageeNewark$967
- Lauren TavaniNewark$850
- Madison GoudyNewark$658
- Sarah StraubNewark$622
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.